Key facts
- This page summarizes Kevin Tang's Form 4 filing for Odonate Therapeutics, Inc..
- 8 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 19 Nov 2021, 15:38.
Kevin Tang - 17 Nov 2021 Form 4 Insider Report for Odonate Therapeutics, Inc.
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 17 Nov 2021
- Net transaction value
- -$5,730,557
- SEC form
- 4
- Accepted by SEC
- 19 Nov 2021, 15:38:52 UTC
- Prior SEC filing
- 01 Jun 2021
- Next SEC filing
- 22 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kevin Tang
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kevin Tang filed Form 4 for Odonate Therapeutics, Inc. on 19 Nov 2021.
Change
- Previous filing in this sequence was filed on 01 Jun 2021.
- Current net transaction value: -$5,730,557.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ODT
transaction
Common Stock
Sale
- Transaction value
- $1,246,341
- Shares
- -468,849
- Change %
- -3%
- Price
- $2.66*
- Shares after
- 15,045,717
- Date
- 17 Nov 2021
- Ownership
- By LP
- Footnotes
- F1, F2
ODT
transaction
Common Stock
Sale
- Transaction value
- $62,118
- Shares
- -31,151
- Change %
- -0.21%
- Price
- $1.99*
- Shares after
- 15,014,566
- Date
- 17 Nov 2021
- Ownership
- By LP
- Footnotes
- F2, F3
ODT
transaction
Common Stock
Sale
- Transaction value
- $1,008,050
- Shares
- -500,000
- Change %
- -3.3%
- Price
- $2.02*
- Shares after
- 14,514,566
- Date
- 17 Nov 2021
- Ownership
- By LP
- Footnotes
- F2, F4
ODT
transaction
Common Stock
Sale
- Transaction value
- $632,238
- Shares
- -287,577
- Change %
- -2%
- Price
- $2.20*
- Shares after
- 14,226,989
- Date
- 17 Nov 2021
- Ownership
- By LP
- Footnotes
- F2, F5
ODT
transaction
Common Stock
Sale
- Transaction value
- $418,643
- Shares
- -212,423
- Change %
- -1.5%
- Price
- $1.97*
- Shares after
- 14,014,566
- Date
- 18 Nov 2021
- Ownership
- By LP
- Footnotes
- F2, F6
ODT
transaction
Common Stock
Sale
- Transaction value
- $940,600
- Shares
- -500,000
- Change %
- -3.6%
- Price
- $1.88*
- Shares after
- 13,514,566
- Date
- 18 Nov 2021
- Ownership
- By LP
- Footnotes
- F2, F7
ODT
transaction
Common Stock
Sale
- Transaction value
- $722,636
- Shares
- -381,842
- Change %
- -2.8%
- Price
- $1.89*
- Shares after
- 13,132,724
- Date
- 18 Nov 2021
- Ownership
- By LP
- Footnotes
- F2, F8
ODT
transaction
Common Stock
Sale
- Transaction value
- $699,930
- Shares
- -365,289
- Change %
- -2.8%
- Price
- $1.92*
- Shares after
- 12,767,435
- Date
- 19 Nov 2021
- Ownership
- By LP
- Footnotes
- F2, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein.
Footnote F2
The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
Footnote F3
The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005.
Footnote F4
The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07.
Footnote F5
The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33.
Footnote F6
The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16.
Footnote F7
The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99.
Footnote F8
The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001.
Footnote F9
The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985.